Anglo-Swedish drugs developer AstraZeneca said its Zinforo skin infection treatment has been given a positive verdict by the Committee for Medicinal Products for Human Use (CHMP).
The CHMP's positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union.
The CHMP reviewed data from the Phase III clinical trial programmes which included four pivotal registration trials, CANVAS 1 and 2 (relating to complicated Skin and Soft Tissue Infections, or cSSTI) and FOCUS 1 and 2 (relating to Community Acquired Pneumonia, or CAP). Clinical data demonstrated that Zinforo was effective and well tolerated in adult patients with cSSTI or CAP, including those patients with more than one underlying disorder.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
"We remain one of the few companies still committed to novel antibiotic research, with one of the world's largest antibacterial pipelines and many strong partnerships to address this significant unmet medical need," noted Martin Mackay, President of Research & Development at Astra.
Astra has been granted exclusive commercial rights and co-exclusive development rights for ceftaroline fosamil (.i.e Zinforo) by Forest Labs for all countries except the USA, Canada and Japan.
AstraZeneca has made regulatory submissions in a number of countries where it has commercialisation rights and further submissions are planned in 2012.
Who is the richest person in the world?
The top five richest people in the world have a combined net worth of $825 billion. Who takes the crown for the richest person in the world?
By Vaishali Varu Published
Top 10 stocks with highest growth over past decade - from Nvidia, Microsoft to Netflix, which companies made you the most money?
We reveal the 10 global companies with the biggest returns since 2013. One firm has posted an astonishing 9,870% return, meaning a £1,000 investment would now be worth almost £82,000.
By Ruth Emery Published